×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Events
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Kevin Wright
When compared with Nexavar, Fotivda showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.
Conor Killmurray
From a new trial in Canada looking at therapeutics to help prevent severe symptoms of COVID-19 in patients with cancer to updated guidelines from the American Cancer Society on taking the HPV vaccine to prevent certain cancers, here’s what’s making the headlines in the cancer space this week.
 
Ryan McDonald
Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and renal cell carcinoma or sporadic papillary renal cell carcinoma.
 
Ryan McDonald
Data from a phase 3 study presented at the 2020 ASCO Virtual Scientific Program showed that treatment with savolitinib demonstrated encouraging efficacy and an improved safety over standard-of-care Sutent (sunitinib) in patients with MET-driven papillary renal cell carcinoma.
 
Jessica Skarzynski
Researchers indicate that the current data suggest that race does not have a negative prognostic effect in patients with castration-resistant prostate cancer with bone metastases.
 
Jessica Skarzynski
Tired of throwing out overripe, brown bananas? This simple and delicious recipe for banana oatmeal muffins from the oncology dietitians at the John Theurer Cancer Center will put them to good use.
 
Jessica Skarzynski
“We're not going to turn our back on our cancer patients, we're not going to make it a choice between COVID and cancer, but rather we're going to make it and we have to treat both,” said Dr. Pat Basu, President and CEO of Cancer Treatment Centers of America.
 
Ryan McDonald
The risk for a major cardiovascular event was reduced by more than half in patients who received Relumina compared to the hormone associated therapy leuprolide.
 
Ryan McDonald
A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.
 
Jessica Skarzynski
The Food and Drug Administration approved the oral combination of Inquovi (Dacogen [decitabine] and cedazuridine) for certain adult patients with myelodysplastic syndromes (MDS).
 
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×